Ex-Ax­o­vant crew at Arvelle ups Se­ries A haul, de­ploy­ing $200M-plus to com­mer­cial­ize epilep­sy drug in Eu­rope

One of the char­ac­ter­is­tic fea­tures of the sprawl­ing biotech group Vivek Ra­maswamy has built at Roivant is its abil­i­ty to whip up big-mon­ey fi­nanc­ing deals for its sub­sidiaries. Ax­o­vant was a prime ex­am­ple, rais­ing $315 mil­lion in an IPO — a mon­ster by 2015 and even to­day’s stan­dards — with an Alzheimer’s pitch be­fore a spec­tac­u­lar flop forced the com­pa­ny to re­plot its course di­rect­ly and piv­ot to gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER